Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia. by 媛뺤��꽍 et al.
RESEARCH ARTICLE
Effects of Omega-3 Fatty Acid
Supplementation on Diabetic Nephropathy
Progression in Patients with Diabetes and
Hypertriglyceridemia
Eugene Han1,5☯, Yujung Yun1☯, Gyuri Kim1,5, Yong-ho Lee1, Hye Jin Wang2, Byung-
Wan Lee1,3,5, Bong Soo Cha1,3,5, Beom Seok Kim4, Eun Seok Kang1,3,5*
1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of
Medicine, Seoul, Korea, 2 Brain Korea 21 Project for Medical Science, Yonsei University College of
Medicine, Seoul, Korea, 3 Institute of Endocrine Research, Yonsei University College of Medicine, Seoul,
Korea, 4 Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine,
Seoul, Korea, 5 Graduate school, Yonsei University College of Medicine, Seoul, Korea
☯ These authors contributed equally to this work.
* edgo@yuhs.ac
Abstract
Beneficial effects of omega-3 fatty acid (O3FA) supplementation in a wide range of disease
condition have been well studied. However, there is limited information regarding the effects
of O3FAs on chronic kidney disease (CKD), especially in diabetic nephropathy (DN) with
hypertriglyceridemia. We investigate whether O3FA supplementation could help maintain
renal function in patients with diabetes and hypertriglyceridemia. Total 344 type 2 diabetic
patients with a history of O3FA supplementation for managing hypertriglyceridemia were
included. Reduction in urine albumin to creatinine ratio (ACR) and glomerular filtrate rate
(GFR) were examined. Subgroup analyses were stratified according to the daily O3FA
doses. Serum total cholesterol, triglyceride, and urine ACR significantly reduced after O3FA
supplementation. Overall, 172 (50.0%) patients did not experience renal function loss, and
125 (36.3%) patients had a GFR with a positive slope. The patients treated with O3FAs at
4g/day showed greater maintenance in renal function than those treated with lower dosages
(p < 0.001). This dose dependent effect remains significant after adjustment for multiple var-
iables. O3FA supplementation in diabetic patients with hypertriglyceridemia shows benefits
of reducing albuminuria and maintaining renal function. The effects are dependent on the
dose of daily O3FA supplementation.
Introduction
Chronic kidney disease (CKD) is defined as kidney dysfunction present for> 3 months, with a
glomerular filtration rate (GFR)< 60 mL/min/1.73 m2 [1]. Many studies have reported that
both lower GFR and greater albuminuria are independently related to the rates of end-stage
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renal disease (ESRD), cardiovascular events, and mortality. Albuminuria severity is strongly
predictive of poor outcomes at all levels of GFR. More than 40% of subjects with type 2 diabetes
mellitus (DM) develop diabetic nephropathy (DN) [2], which has become the leading cause of
ESRD [3]. DN is characterized by abnormal urinary albumin excretion progressing from
microalbuminuria (30–300 μg/min) to macroalbuminuria (> 300 μg/min) [1]. In addition,
GFR is known to decrease with age, at less than 1 ml/min/1.73 m2/year, in healthy individuals
[4]; this is accelerated in DN to 5.2 ml/min/1.73 m2/year [5]. Nevertheless, early screening and
limited intervention can prevent or delay DN progression in diabetic patients with microalbu-
minuria [6].
Omega-3 fatty acids (O3FAs) are polyunsaturated fatty acids (PUFAs) derived from fish oil;
the three types are α-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA). These are essential fatty acids, and small amounts of dietary O3FAs enable normal
growth. O3FAs also reduce blood triglyceride levels [7–9]. Although somewhat controversial,
regular O3FA supplementation may reduce the risks of myocardial infarction and sudden car-
diac death [10]. Some evidence suggests that it may improve blood circulation; increase the
breakdown of fibrin, a compound involved in clot and scar formation; and reduce blood pres-
sure and heart rate [11–13]. Hypertension is a major risk factor for CKD development, and it is
expected that O3FAs could inhibit CKD progression due to their anti-hypertensive effect.
Numerous studies have evaluated the potential beneficial effects of O3FAs on inflammatory,
autoimmune, and renal diseases [14, 15]. O3FAs can reduce proteinuria in patients with
chronic glomerular disease and slow immunoglobulin A (IgA) nephropathy [16]. Due to their
anti-inflammatory effects, O3FAs have been suggested to protect against kidney damage. An
animal model study showed that O3FA supplementation reduced renal inflammation and
fibrosis [17]. In addition, a large community-based cohort study reported that increased die-
tary intake of long-chain n-3 PUFA and fish reduces CKD prevalence [18].
However, there is limited information regarding the effects of O3FAs on CKD, especially in
patients with DN. The role of O3FAs in DN has not been thoroughly investigated. Therefore,
we performed a retrospective cohort study to examine whether O3FA supplementation could
preserve renal function in diabetic subjects.
Materials and Methods
In this retrospective study, subjects were identified by reviewing patient case notes using elec-
tronic medical records at Severance Hospital, a tertiary university hospital in Korea. We
included 344 patients 20 years old with a history of O3FA (highly purified ethyl ester con-
centrate of EPA and DHA) supplementation for managing hypertriglyceridemia. Diabetes mel-
litus (DM) was defined according to the International Classification of Diseases 10th revision
(ICD 10). Only new users who had not used O3FAs in a preceding year were enrolled. The
mean supplement duration (‘after treatment’ period) was 1.9 ± 1.6 years (median 1.4 years).
O3FA was used for at least 3 months. Subjects were excluded if they fulfilled any one of the fol-
lowing criteria: (1) kidney transplanted patient; (2) dialysis patient; (3) intrinsic renal disease
(nephritis or nephrotic syndrome) patient; (4) acute renal failure due to septic shock, contrast
agents, or drugs; and (5) postrenal disease patient. The patient records was anonymized and
de-identified prior to analysis. The study protocol received ethical approval by the institutional
review board at the Yonsei University College of Medicine (4-2014-0273).
Clinical and laboratory parameters
We evaluated the effects of O3FAs on DN and albuminuria. The dose-effect relationships
between O3FAs and albuminuria, renal function were also analyzed. Baseline estimated
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glomerular filtration rates (GFRs), and spot urine ACRs were measured at the start of O3FA
administration. Overnight 8-hours fasting random spot urine samples were collected, and
urine ACR was measured with an immunoturbidimetric method. After O3FA treatment
(median 1.4 years), we evaluated changes in these laboratory parameters and also examined
clinical parameters, blood glucose, lipid profiles. GFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [19]. Body mass index (BMI) was
defined as body weight (kg) divided by the square of height (m2).
Data analysis
The primary outcome was renal function changes during O3FAs supplementation, specifically
in GFR and urine ACR. We compared the annual rates of GFR decline among three dose cate-
gories: 1 g/day, 2 g/day, and 4 g/day. Subgroup analyses were stratified according to daily
O3FA doses; daily doses of 4 g O3FA were grouped into the high-dose group, and those<4 g
were placed in the low-dose group. In addition, the proportion of subjects with preserved GFR
was analyzed according to O3FA dosages.
Statistical analysis
The data are reported as mean ± standard deviation (SD), and the real numbers of participants
with the percentages follow in parentheses. Simple comparisons of continuous variables within
or between sub-groups were made with Student’s t-tests. Paired data measured at baseline and
after O3FA supplementation were compared using paired t tests. Since urine ACR, total choles-
terol, triglyceride, high density lipoprotein (HDL) cholesterol, and high sensitivity C-reactive
protein (hsCRP) values were not normally distributed, analyses were performed using log- and
back-transformed data. Chi-square tests were used to examine the relationships between multi-
ple variables. The relative factor for GFR decline was obtained using univariate and multiple
logistic regressions, and the risk is reported in the form of odds ratios (ORs) and 95% confi-
dence intervals (CIs). All statistical analyses were performed using the SPSS statistical analysis
program (SPSS vs. 20.0, IBM Corp, Armonk, NY). For all tests, p< 0.05 was considered statis-
tically significant.
Results
Subject clinical characteristics
Table 1 shows the baseline clinical characteristics of patients. A total of 344 patients (244
males, 100 females) were recruited with a mean O3FA supplement duration of 1.9 ± 1.6 years.
More than 90% of patients were treated with O3FA< 4 g/day. Three-quarters of patients had
hypertension that was relatively well-controlled (mean systolic blood pressure 127.8 ± 15.1
mmHg, mean diastolic blood pressure 74.9 ± 9.6 mmHg). About 72% of these patients were
using angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers
(ARBs).
Effects of O3FA supplementation on renal function loss
Urine ACR was significantly decreased after O3FA supplementation (from 475.8 ± 1235.9 mg/g
to 385.6 ± 1067.9 mg/g, Δ = -72.1 ± 507.6 mg/g, p = 0.003; Table 2). However, a significant GFR
decline was observed during the study periods (Table 2). The mean annual GFR loss was
2.6 ± 12.7 mL/min/1.73 m2 (median value 0.9 mL/min/1.73 m2). GFR did not decrease in 172
(50.0%) patients and increased in 125 (36.3%) patients after O3FA supplementation. We also
analyzed the baseline characteristics of study groups stratified by whether GFR was preserved
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Table 1. Baseline characteristics of study subjects.
Baseline Parameters Values
Male gender, N (%) 244 (70.9)
Age (year) 56.8 ± 11.8
DM duration (year) 6.5 ± 7.6
O3FAs dosage 1875.0 ± 796.5
1 g/day, N (%) 103 (29.9)
2 g/day, N (%) 211 (61.3)
4 g/day, N (%) 30 (8.7)
BMI (kg/m2) 26.0 ± 3.4
Smoking, N (%) 152 (44.2)
Drinking alcohol, N (%) 147 (42.7)
Hypertension, N (%) 256 (74.4)
Systolic blood pressure (mmHg) 127.8 ± 15.1
Diastolic blood pressure (mmHg) 74.9 ± 9.6
Medications, N (%)
ACEi/ARB 247 (71.8)
CCB 151 (43.9)
SU 154 (44.8)
Metformin 268 (77.9)
DPP4i 126 (36.6)
TZD 46 (13.4)
Insulin 59 (17.2)
Fenoﬁbrate 54 (15.7)
Statin 211 (61.3)
Ezetimibe 42 (12.2)
Data are presented as N (%) or mean ± SD. DM, diabetes mellitus; O3FAs, omega-3 fatty acids; BMI, body
mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB,
calcium channel blocker; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.
doi:10.1371/journal.pone.0154683.t001
Table 2. Changes in clinical parameters before and after O3FAs supplement.
Parameters Before After Difference P
Urine ACR (mg/g) 475.8 ± 1235.9 385.6 ± 1067.9 -72.1 ± 507.6 <0.001
Urine ACR, log- transformed 4.0 ± 2.0 3.8 ± 2.0 0.003
GFR (mL/min/1.73 m2) 76.1 ± 25.9 74.4 ± 27.9 -1.8 ± 11.2 0.004
Fasting blood glucose (mg/dL) 141.2 ± 50.9 129.7 ± 36.6 -11.5 ± 3.0 <0.001
Postprandial blood glucose (mg/dL) 223.6 ± 84.7 208.2 ± 66.1 -15.3 ± 91.4 0.020
HbA1c (%) 7.8 ± 6.3 7.1 ± 1.1 -0.6 ± 6.3 0.084
Total cholesterol (mg/dL) 187.6 ± 55.9 158.8 ± 41.1 -28.8 ± 55.3 <0.001
Total cholesterol, log-transformed 5.2 ± 0.3 5.0 ± 0.3 <0.001
Triglyceride (mg/dL) 417.9 ± 646.5 227.4 ± 172.3 -190.4 ± 633.1 <0.001
Triglyceride, log-transformed 5.8 ± 0.7 5.2 ± 0.6 <0.001
HDL cholesterol (mg/dL) 41.1 ± 22.1 40.4 ± 12.7 -0.7 ± 23.9 0.573
HDL cholesterol, log-transformed 3.7 ± 0.3 3.7 ± 0.3 0.975
Uric acid (mg/dL) 6.02 ± 1.74 5.80 ± 1.59 -0.21 ± 1.42 0.006
hsCRP (mg/L) 5.9 ± 14.4 2.4 ± 8.3 -3.5 ± 15.3 0.004
hsCRP, log transformed 0.5 ± 1.4 0.1 ± 1.0 <0.001
Data are presented as N (%) or mean ± SD. O3FA, omega-3 fatty acid; ACR, albumin to creatinine ratio; GFR, glomerular ﬁltration rate; HbA1c, glycated
hemoglobin; HDL cholesterol, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein.
doi:10.1371/journal.pone.0154683.t002
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(S1 Table). There were no significant differences in baseline parameters according to the presence
of GFR loss in renal function, except for diabetes duration, O3FAs dose, systolic blood pressure,
and urine ACR. The shorter diabetes duration and lower urine ACR the patients had, the greater
the benefit to preserving GFR was observed (S1 Table). Greater maintenance of renal function
was observed in the high dose group (Table 3). The annual decline in GFR ranged from
3.6 ± 10.8 mL/min/1.73 m2 in the 1 g/day group to 2.6 ± 13.7 mL/min/1.73 m2 in the 2 g/day
group. For the 4 g/day group, the GFR decline was -0.3 ± 11.5 mL/min/1.73 m2. However, there
was no statistically significant difference in annual GFR loss among these three groups. The pro-
portions of patients without GFR decline were 37.9%, 54.0%, and 63.3% in the 1 g/day, 2 g/day
and 4 g/day groups, respectively (p = 0.006 for trend). Univariate logistic regression analysis was
performed to identify variables associated with kidney function loss (Table 3). In terms of GFR
loss, O3FA doses of 2 g/day (OR = 0.52, 95% CI 0.32–0.84, p = 0.008) and 4 g/day (OR = 0.35,
95% CI 0.15–0.82, p = 0.015) were beneficial, whereas longer diabetes duration, higher systolic
blood pressure, and fenofibrate use had a negative effect (Table 3). Next, we sought to confirm
the efficacy of high-dose O3FAs on DN. As shown in S2 Table, patients treated with high doses
of O3FAs tended to have increased baseline triglycerides and fenofibrate use. Multivariable logis-
tic regression models were applied to adjust for other conventional confounding covariates that
affect DN, along with fenofibrate, statin use, and triglycerides levels (Table 4). O3FA at 2 g/day
had a positive effect on GFR preservation (OR = 0.43, 95% CI 0.26–0.74, p<0.05), on which
O3FA at 4 g/day showed a markedly higher benefit (OR = 0.20, 95% CI 0.08–0.52, p<0.05). The
same trends were observed in patients without fenofibrate use (S3 Table).
Effects of O3FA supplementations on metabolic parameters
At enrollment, 61.3% of patients were using statins, and 15.7% used fenofibrate. Serum triglyc-
eride levels were 46% lower after O3FA supplementation (p< 0.001), and total cholesterol
decreased by 19% (p< 0.001). There were no significant changes in HDL cholesterol after
Table 3. Univariate logistic regression analysis to determine variables associated with GFR decline.
OR 95% CI P
O3FAs dosage
1 g/day Reference
2 g/day 0.52 0.32–0.84 0.008
4 g/day 0.35 0.15–0.82 0.015
Age (year) 0.99 0.98–1.01 0.505
Sex (female) 1.12 0.70–1.79 0.635
Diabetes duration (year) 1.05 1.02–1.09 0.001
Systolic blood pressure (mmHg) 1.01 1.00–1.03 0.037
ACEi/ARB use 1.14 0.72–1.79 0.564
Statin use 1.08 0.70–1.67 0.740
Fenoﬁbrate use 2.04 1.12–3.70 0.019
Fasting blood glucose 1.00 1.00–1.01 0.056
HbA1c 0.99 0.96–1.02 0.452
Baseline GFR 0.66 0.41–1.08 0.097
Baseline triglyceride 1.15 0.84–1.59 0.371
O3FA, omega-3 fatty acid; OR, odds ratio; 95% CI, 95% conﬁdence interval; ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker; HbA1c, glycated hemoglobin; GFR, glomerular
ﬁltration rate.
doi:10.1371/journal.pone.0154683.t003
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O3FA treatment (Table 2). However, uric acid levels and hsCRP were significantly reduced
(All ps< 0.05, Table 2).
Discussion
The major finding of this study is that O3FA supplementation may help with preserving renal
function in type 2 diabetes patients with hypertriglyceridemia. O3FA influenced both urine
ACR and GFR, indicating a protective effect for O3FA on DN. In addition, the effects were
dependent on the dose of daily O3FA supplementation. Although GFR decline was observed in
our study population, the mean annual rate of GFR decline was relatively slower than that
reported in a previous study [5].
A possible association between O3FA supplementation and albuminuria reduction was first
noticed after EPA was found to improve albuminuria in diabetic patients [20]. After EPA was
administered to 16 diabetic patients (5 type 1 and 11 type 2) for 6 months, albuminuria mea-
sured with spot urine was significantly improved without altering blood glucose levels, body
weight, or blood pressure. A large nested control study including 1,150 type 1 DM subjects
showed that higher n-3 PUFA intake was related to a lower risk of microalbuminuria [21].
There are also some studies supporting the hypothesis that O3FA supplementation slows the
progression of IgA nephropathy. For IgA nephropathy patients with persistent proteinuria,
fish oil supplementation for 2 years delayed nephropathy progression compared to olive oil
supplementation, and this effect appeared to be independent of reduced blood pressure [16]. A
meta-analysis showed n-3 PUFA reduces urine protein excretion among IgA nephropathy,
DM, and lupus nephritis patient populations [22]. In addition, O3FA supplementation report-
edly reduces DM complications [23]. The pathway of beneficial effects of O3FA in kidney has
been studied in animal experiments: improvement of dyslipidemia and attenuation of inflam-
mation. Streptozotocin-induced diabetic rats fed a high n-3 PUFA diet were more resistant to
renal disease development [24]. N-3 PUFA treatment attenuated diabetes-associated glomeru-
losclerosis and tubulointerstitial fibrosis [24]. In addition, after n-3 PUFA supplementation,
expression levels of transforming growth factor (TGF)-β, which is a marker of end-organ com-
plications associated with DM, and those of interleukin (IL)-6 and monocyte chemoattractant
protein (MCP)-1, markers of tissue inflammation, were attenuated [24]. Similarly, in DN of
type 2 diabetic KKAy/Ta mice model, improved urine ACR and down regulated MCP-1 levels
were observed [25]. Mesangial matrix accumulation and tubule-interstitial fibrosis were atten-
uated in EPA-injected mice, but where were no alterations in systolic blood pressure or fasting
Table 4. Multiple logistic regression analysis to determine variables associated with GFR decline.
O3FA 2 g/day O3FA 4 g/day
OR (95% CI) P OR (95% CI) P
Model 1 0.51 (0.32–0.83) 0.007 0.34 (0.15–0.79) 0.013
Model 2 0.47 (0.28–0.77) 0.003 0.21 (0.08–0.54) 0.001
Model 3 0.43 (0.26–0.74) 0.002 0.20 (0.08–0.52) 0.001
Reference group = patients with O3FA 1g/day; Model 1: adjusted for age and sex; Model 2: adjusted for
age, sex, diabetes duration, body mass index, systolic blood pressure, angiotensin-converting enzyme
inhibitor/angiotensin II receptor, and statin and fenoﬁbrate use; Model 3: adjusted for age, sex, diabetes
duration, body mass index, systolic blood pressure, angiotensin-converting enzyme inhibitor/angiotensin II
receptor, statin, fenoﬁbrate, fasting blood glucose, baseline GFR, triglycerides, and total cholesterol. GFR,
glomerular ﬁltration rate; O3FAs, omega-3 fatty acids; OR, odds ratio; 95% CI, 95% conﬁdence interval.
doi:10.1371/journal.pone.0154683.t004
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blood glucose levels [25]. Moreover, O3FA fed db/db mice showed reductions in renal triglyc-
erides and renal SREBP-1 expression, as well as attenuation of podocyte injury [26]. In our
study, although levels were only measured in half of the patients hsCRP levels were signifi-
cantly reduced after O3FAs supplementation.
The dose-related effect of O3FAs on DN has not been studied, but it has been investigated
in the context of heart disease. According to the American Heart Association guideline, con-
suming 2 servings (8 ounces) of food containing very long-chain O3FAs reduces the risks of
sudden death and death from coronary artery disease [27]. The mechanisms by which O3FAs
influence cardiovascular disease include amelioration of arrhythmias, thrombosis, inflamma-
tory responses, triglycerides, remnant lipoprotein levels, low-density lipoprotein cholesterol,
atherosclerotic plaque instability, endothelial dysfunction, and blood pressure [28, 29]. Among
these factors, lowered triglyceride efficacy is thought to be a dose-response effect of O3FAs
[30]. In previous studies, 4 g/day of O3FAs reduced serum triglyceride levels by up to 30% [31–
34]. A comparison study of O3FAs dose-response effects on triglycerides in healthy individuals
demonstrated that high-dose (3.4 g/day) O3FAs significantly decreased triglyceride, whereas
there were no changes in blood triglyceride levels in the placebo or low-dose (0.85 g/day)
groups [35].
Studies suggest that statin could reduce albuminuria and slow down kidney function loss
[36–38]. In subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation
study (GRACE), creatinine clearance increased in patients with statin use (4.9%, p = 0.003)
[36]. Interestingly, among statin users, patients treated with atorvastatin experienced better
renal outcomes, with a 12% increase in creatinine clearance (p<0.001) [36]. The renoprotec-
tive effect of statin is based on the fact that dyslipidemia and hypertension accelerate renal
function loss [38]. In our study, 78 subjects were prescribed atorvastatin (37.0%) among
patients treated with any statin. The proportions of those with preserved GFR were 51.1% for
non-statin users and 49.3% for stain users (p = 0.740). In addition, 48.7% of atorvastatin
(median dose 10 mg/day) users showed preserved GFR, which was similar to that for other
statin users (49.6%) (p = 0.899). The median dose of atorvastatin in our study was 10 mg/day,
which was lower than that in a previous study (24 mg/day) [36]. As the lipid lowering effect of
atorvastatin depends on the daily dose [37], the difference in atorvastatin dose would lead to
discordant results. Meanwhile, the association between fenofibrate, another lipid lowering
drug, and renoprotective effect is controversial [39–42]. It might reduce albuminuria by antiox-
idant and anti-inflammatory mechanisms, in addition to a hypertriglyceridemia lowering effect
[39, 40]. In an international study on type 2 diabetes patients, a fenofibrate treatment group
experienced 2.6% regression or no progression in renal function deterioration, compared to a
placebo group (p = 0.002) [41]. Moreover, 5-year use of fenofibrate was found to reduce albu-
minuria and inhibit GFR decline independently from ACE inhibitor/ARB use [39]. However,
others have reported decreases in creatinine clearance and GFR with fenofibrate use [42]. In
our study, as shown in univariate analysis (Table 3), fenofibrate use showed a negative effect on
preserving renal function. We then conducted subgroup analysis excluding subjects with feno-
fibrate use. Therein, as shown in S3 Table, O3FA supplement was still associated with main-
taining kidney function in a dose dependent manner.
Conversely, there are some reports that O3FA supplementation is not associated with
reduced albuminuria or that this effect is not dose-dependent. A cohort study assessed both
type 1 and 2 DM patients with microalbuminuria and reported that treatment with 4 g/day of
O3FAs did not improve albuminuria [43]. However, the study enrolled a small number of
patients, and the total treatment duration was only 12 weeks. A randomized trial assessing
severe IgA nephropathy patients showed no additional benefit of high-dose O3FA supplemen-
tation [44]. In our data, O3FAs reduced urine ACR or preserved GFR was mostly observed in
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patients with early DN. This might explain why O3FAs did not have dose-dependent effects in
patients with severe IgA nephropathy. In a randomized trial with type 2 diabetes patients, 4 g/
day of n-3 PUFA supplement during 6 weeks did not show significant changes in urine ACR
[45]. However, there was significant improvement in serum renal damage markers, suggesting
the beneficial effect of n-3 PUFA on renal function.
Our study had several limitations. Because it was a retrospective investigation, there were
many critical confounders influencing albuminuria or nephropathy. First, ACE inhibitors and
ARBs are known to ameliorate albuminuria in DN. More than half of patients (71.8%) were
prescribed those medications. Although there were no differences in medication use between
the GFR decline progression and no-progression groups, we analyzed ACE inhibitor or ARB
use as a covariate factor. Second, medication compliance was not fully considered. As this was
not a prospective study, we could not assess adherence with the prescribed O3FA. The study
data were based on the proposition that all the prescribed medication was administrated to the
subjects. Third, hyperglycemia was improved in the course of the study. Fasting and postpran-
dial blood glucose levels were significantly decreased after O3FAs supplementation. There is a
possibility that improved hyperglycemia may contribute to renal function maintain. However,
the correlation analysis showed that improvement in serum triglyceride level is more closely
associated with better GFR maintain after adjustment fasting blood glucose reduction (r = 0.18,
p = 0.001). Fourth, most patients enrolled in this study were relatively early stage DN, as 77.9%
of patients were treated with metformin (contraindicated for advanced kidney disease patients)
and> 70% of patients were normo-, or microalbuminuria or CKD stage I or, II. In addition,
we did not include a control group. However, it would be immoral practice to prescribe a pla-
cebo to patients with hypertriglyceridemia, especially to subjects with serum triglyceride more
than 500 mg/dl, due to the risk of acute pancreatitis.
Our study also had a major strength. We showed dose dependency in O3FAs effects on
attenuating GFR loss. This is the first study reporting an association between O3FA supple-
mentation dosages and DN. A novel finding is the identification of an effective O3FA dose in
DN patients with hypertriglyceridemia. In addition, we enrolled compliant patients without
other kidney diseases who were selected based on detailed reviews of their medical records.
In conclusion, our findings demonstrate that O3FA supplementation in diabetic patients
with hypertriglyceridemia ameliorated urine ACR and preserved GFR. This suggests that
O3FA supplementation in diabetic patients with hypertriglyceridemia could ameliorate DN
progression in a dose-dependent manner. However, further randomized trials are needed to
quantify this beneficial effect compared to placebo and control groups. If there is clear dose-
dependent effect of O3FAs on DN, high-dose O3FA administration will likely provide a thera-
peutic option for high-risk diabetic patients.
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index, systolic blood pressure, angiotensin-converting enzyme inhibitor/angiotensin II recep-
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blood pressure, angiotensin-converting enzyme inhibitor/angiotensin II receptor, statin, fenofi-
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filtration rate; O3FAs, omega-3 fatty acids; OR, odds ratio; 95% CI, 95% confidence interval.
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